tiprankstipranks
pc:adc0v

Adcendo ApS

Adcendo ApS is a biotechnology company developing first- and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. The company is advancing a clinical ADC pipeline including programs ADCE-T02 (Tissue Factor), ADCE-D01 (uPARAP), and ADCE-B05, focusing on dose escalation and expansion studies across multiple tumor indications.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$75M
Total Amount Raised$75M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$75M
Latest Funding Amount$75M
Latest Funding RoundSeries C
Latest Funding RoundSeries C
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Apr 14, 2026
Series C
$75.00M

Investors

Investor Name
Funding Round
Series C
Series C

Related News and Analysis